CoChat

Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes

Open access
Rossetti, Paolo, Porcellati, Francesca, Bolli, Geremia B., Fanelli, Carmine G. · 2008 · Diabetes Care
Cited by 55

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Insulin therapy in diabetes, both at on-set and after several years ’ duration, isprimarily directed to maintain near-normoglycemia to prevent the onset and/or delay progression of long-term complications (1,2). However, it is im-portant that regimens of insulin therapy are designed not only to aim at near-normalizing blood glucose, but also to minimize the risk of hypoglycemia. Sub-jects with type 1 diabetes continuously drift between hyperglycemia and hypo-glycemia. If the former prevails, long-term complications are frequently expected (1). On the other hand, hypo-glycemia is not only dangerous and un-pleasant, but may over time lead to the syndrome of hypoglycemia unawareness (3). This is relevant in type 1 diabetes but also in type 2 diabetes, since over time, many type 2 diabetic subjects develop progressive pancreatic -cell dysfunction requiring insulin therapy. Because in sub-jects with advanced type 2 diabetes the neuroendocrine responses to hypoglyce-mia are as abnormal as in type 1 diabetic patients (4), insulin therapy may become responsible for frequent and/or severe hy-poglycemia in type 2 diabetic patients as well. The goal of minimizing the risk of hy-poglycemia while achieving good glyce-mic control is feasible as long as 1) a rational plan of insulin therapy is adopted, 2) blood glucose is properly monitored, 3) blood glucose targets are individualized, and 4) education pro-grams are widely implemented. In the present article, the importance of the use of insulin analogs as a key tool to achieve good glycemic control and pre-vent hypoglycemia is emphasized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-s227

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 46

  1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986, 1993 · DOI · Paper page
  2. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:468–477, 1999 · DOI · Paper page
  3. Fanelli CG, Pampanelli S, Porcellati F, Rossetti P, Brunetti P, Bolli GB: Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. Ann Intern Med 136:504–514, 2002 · DOI
  4. Spyer G, Hattersley A, MacDonald I, Amiel S, MacLeod H: Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 356:1970–1974, 2000 · DOI · Paper page
  5. Gerich J: Hypoglycemia and counter regulation in type 2 diabetes. Lancet 356:1946–1947, 2000 · DOI
  6. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK: Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 21:574–579, 1998 · DOI · Paper page
  7. UKPDS Research Group: Effort of intensive blood glucose control with insulin and sulfonylureas on insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998 · DOI · Paper page
  8. Hepburn DA, MacLeod KM, Pell ACH, Scougal IJ, Frier BM: Frequency and symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10:231–237, 1993 · DOI · Paper page
  9. Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI: Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 44:180–184, 1995 · DOI
  10. De Feo P, Perriello G, De Cosmo S, Ventura MM, Campbell PJ, Brunetti P, Gerich JE, Bolli GB: Comparison of glucose counterregulation during short-term and prolonged hypoglycemia in normal humans. Diabetes 35:563–569, 1986 · DOI
  11. Fanelli C, Calderone S, Epifano L, De Vincenzo A, Modarelli F, Pampanelli S, Perriello G, De Feo P, Brunetti P, Gerich JE, Bolli GB: Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. J Clin Invest 92:1617–1622, 1993 · DOI · Paper page
  12. Fruehwald-Schultes B, Born J, Kern W, Peters A, Fehm HL: Adaptation of cognitive function to hypoglycemia in healthy men. Diabetes Care 23:1059–1066, 2000 · DOI · Paper page
  13. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J: Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 42:1233–1237, 1993 · DOI
  14. Fanelli CG, Paramore DS, Hershey T, Terkamp C, Ovalle F, Craft S, Cryer PE: Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes 47:1920–1927, 1998 · DOI · Paper page
  15. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA: Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 344:283–287, 1994 · DOI · Paper page
  16. Mitrakou A, Fanelli C, Veneman T, Perriello G, Calderone S, Platanisiotis D, Rambotti A, Raptis S, Brunetti P, Cryer P, Gerich PE, Bolli GB: Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 329:834–839, 1993 · DOI · Paper page
  17. Gold AE, MacLeod KM, Frier BM: Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 17:697–703, 1994 · DOI · Paper page
  18. McCall A, Fixman L, Fleming N, Tornheim K, Click W, Ruderman NB: Chronic hypoglycemia increases brain glucose transport. Am J Physiol 251:E442–E447, 1986 · DOI · Paper page
  19. McCall AL, Millington WR, Wurtman RJ: Metabolic fuel and amino acid transport into the brain in experimental diabetes mellitus. Proc Natl Acad Sci U S A 79:5406–5410, 1982 · DOI · Paper page
  20. Vannucci SJ, Maher F, Simpson IA: Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21:2–21, 1997 · DOI · Paper page
  21. McCall AL, Fixman LB, Fleming N, Fleming L, Click W, Ruderman NB: Chronic hypoglycemia increases brain glucose transport. Am J Physiol 251:E442–E447, 1986 · DOI · Paper page
  22. Uehara Y, Nipper V, McCall AL: Chronic insulin hypoglycemia induces GLUT-3 protein in rat brain neurons. Am J Physiol 272:E716–E719, 1997 · DOI · Paper page
  23. Boyle PJ, Kempers SF, O’Connor AM, Nagy RJ: Brain glucose uptake and unawareness of hypoglycemia in patients with insulin dependent diabetes mellitus. N Engl J Med 333:1726–1731, 1995 · DOI · Paper page
  24. Segel SA, Fanelli CG, Dence CS, Markham J, Videen TO, Paramore DS, Powers WJ, Cryer PE: Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 50:1911–1917, 2001 · DOI · Paper page
  25. Fanelli CG, Dence CS, Markham J, Videen TO, Paramore DS, Cryer PE, Powers WJ: Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes. Diabetes 47:1444–1450, 1998 · DOI · Paper page
  26. Bingham EM, Dunn JT, Smith D, Sutcliffe-Goulden J, Reed LJ, Marsden PK, Amiel SA: Differential changes in brain glucose metabolism during hypoglycemia accompany loss of hypoglycemia awareness in men with type 1 diabetes mellitus: an [11C]-3-O-methyl-d-glucose PET study. Diabetologia 48:2080–2089, 2005 · DOI
  27. Raju B, McGregor VP, Cryer PE: Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure. Diabetes 52:2083–2089, 2003 · DOI · Paper page
  28. Goldberg PA, Weiss R, McCrimmon RJ, Hintz EV, Dziura JD, Sherwin RS: Antecedent hypercortisolemia is not primarily responsible for generating hypoglycemia-associated autonomic failure. Diabetes 55:1121–1126, 2006 · DOI · Paper page
  29. McCrimmon RJ, Song Z, Cheng H, McNay EC, Weikart-Yeckel C, Fan X, Routh VH, Sherwin RS: Corticotrophin-releasing factor receptors within the ventromedial hypothalamus regulate hypoglycemia-induced hormonal counterregulation. J Clin Invest 116:1723–1730, 2006 · DOI · Paper page
  30. Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA: Lactate: a preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab 23:658–664, 2003 · DOI · Paper page
  31. Tsacopoulos M, Magistretti PJ: Metabolic coupling between glia and neurons. J Neurosci 16:877–885, 1996 · DOI · Paper page
  32. Walz W, Murkerji S: Lactate production and release in cultured astrocytes. Neurosci Lett 86:296–300, 1988 · DOI
  33. Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL, Stella N, Magistretti PJ: Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci 20:291–299, 1998 · DOI · Paper page
  34. Lubow JM, Pinon IG, Avogaro A, Cobelli C, Treeson DM, Mandeville KA, Toffolo G, Boyle PJ: Brain oxygen utilization is unchanged by hypoglycemia in normal humans: lactate, alanine, and leucine uptake are not sufficient to offset energy deficit. Am J Physiol Endocrinol Metab 290:E149–E153, 2006 · DOI · Paper page
  35. Choi IY, Gruetter R: In vivo 13C NMR assessment of brain glycogen concentration and turnover in the awake rat. Neurochem Int 43:317–322, 2003 · DOI
  36. Clarke DD, Sokoloff L: Circulation and energy metabolism of the brain. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 5th ed. Siegel G, Agranoff B, Albers RW, Molinoff P, eds. New York, Raven Press, 1994, p. 645–652
  37. Cryer PE: Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious cycle. Diabetes 41:255–260, 1992 · DOI · Paper page
  38. Pampanelli S, Fanelli C, Lalli C, Ciofetta M, Sindaco PD, Lepore M, Modarelli F, Rambotti AM, Epifano L, Di Vincenzo A, Bartocci L, Annibale B, Brunetti P, Bolli GB: Long-term intensive insulin therapy: effects of HbA1c risk for severe and mild hypoglycemia, status of counterregulation and unawareness of hypoglycemia. Diabetologia 39:677–686, 1996 · DOI
  39. Bolli GB, Di Marchi R, Park G, Pramming S, Koivisto VA: Insulin analogs and their potential in the management of diabetes mellitus. Diabetologia 42:1151–1167, 1999 · DOI · Paper page
  40. Becker RHA: Insulin glulisine complementing basal insulin: a review of structure and activity. Diabetes Technol Ther 9:109–121, 2007 · DOI · Paper page
  41. Porcellati F, Rossetti P, Busciantella Ricci N, Pampanelli S, Torlone E, Herdandez Campos S, Marinelli Andreoli A, Bolli GB, Fanelli CG: Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after one week of use as compared to its first administration in subjects with type 1 diabetes mellitus. Diabetes Care 30:1261–1263, 2007 · DOI · Paper page
  42. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG: Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30:2447–2452, 2007 · DOI · Paper page
  43. Ashwell SG, Gebbie J, Home PD: Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med 23:879–886, 2006 · DOI · Paper page
  44. García-García E, Galera R, Aguilera P, Cara G, Bonillo A: Long-term use of continuous subcutaneous insulin infusion compared with multiple daily injections of glargine in pediatric patients. J Pediatr Endocrinol Metab 20:37–40, 2007 · DOI
  45. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW: Insulin Aspart CSII/MDI Comparison Study Group: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 28:533–538, 2005 · DOI · Paper page
  46. Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA: A randomized pilot study in type 1 diabetes complicated by severe hypoglycemia, comparing rigorous hypoglycemia avoidance with insulin analog therapy, CSII or education alone. Diabet Med 24:778–783, 2007 · DOI · Paper page

Cited by

See all 55

Metadata

Authors
Rossetti, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G.
Venue
Diabetes Care
Published
2008-02-01
Volume
31
Issue
Supplement_2
Pages
S113-S120
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2112217619
Cited by
55
References
24
FWCI
5.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc08-s227
The paper
Rossetti, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2008). Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc08-s227

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.